When will the patents on EVENITY expire, and when will biosimilar EVENITY launch?

Sponsor	Phase
Amgen	PHASE2
Nitin Agarwal	PHASE2
Beckwith Foundation	PHASE2

Last updated: September 8, 2026

EVENITY, or romosozumab-aqqg, is Amgen and UCB’s monthly injectable biologic for postmenopausal women with osteoporosis at high fracture risk. The product has become a billion-dollar franchise, supported by strong fracture-reduction data and a differentiated bone-building mechanism. Its principal commercial constraints are the 12-month treatment limit, cardiovascular labeling, the need for follow-on antiresorptive therapy, and competition from Prolia, anabolic agents, and lower-cost oral drugs.

Amgen reported approximately $1.0 billion in global EVENITY sales in 2023, compared with roughly $0.75 billion in 2022. The product remains in a growth phase, but its long-term trajectory depends on broader use earlier in the treatment sequence and continued adoption outside the United States. [1]

What is EVENITY and how does romosozumab work?

EVENITY is a humanized monoclonal antibody against sclerostin. By inhibiting sclerostin, romosozumab increases bone formation and reduces bone resorption during the treatment period. The product is administered as two consecutive subcutaneous injections once each month.

The FDA approved EVENITY in April 2019 for the treatment of osteoporosis in postmenopausal women at high risk for fracture, defined in the label to include a history of osteoporotic fracture, multiple risk factors for fracture, or failure or intolerance of other osteoporosis therapies. [2]

The U.S. label limits treatment to 12 monthly doses. Patients who require additional osteoporosis therapy after the 12-month course should transition to an antiresorptive agent. This treatment sequence is central to the product’s commercial model:

EVENITY provides an initial bone-building course.
Prolia, bisphosphonates, or another antiresorptive therapy maintains bone-density gains.
The prescriber may continue a patient on Amgen’s Prolia after EVENITY, creating potential portfolio retention.

EVENITY carries a boxed warning for increased risk of myocardial infarction, stroke, and cardiovascular death. It should not be initiated in patients who had a myocardial infarction or stroke within the previous year. The cardiovascular warning limits prescribing in patients with significant cardiovascular risk and gives competing therapies an important positioning advantage. [2]

How large is the EVENITY market?

The relevant market is the treatment market for postmenopausal osteoporosis, particularly patients at high or very high fracture risk. It includes:

Prolia, denosumab, marketed by Amgen.
Forteo, teriparatide, originally marketed by Eli Lilly and now subject to generic and follow-on competition.
Tymlos, abaloparatide, marketed by Radius Health.
Bisphosphonates such as alendronate, risedronate, and zoledronic acid.
Romosozumab products in markets where EVENITY is approved.

EVENITY is not a mass-market first-line osteoporosis product. Oral bisphosphonates and generic therapies remain common because of their low cost, established clinical use, and broad reimbursement. The principal target is the higher-value segment in which fracture risk justifies an anabolic or bone-forming agent.

Commercial positioning versus Prolia

Prolia is the strongest internal comparator because it is also marketed by Amgen and is used broadly in osteoporosis maintenance. Prolia is administered every six months and does not have the same 12-month treatment restriction, although discontinuation without follow-on therapy can cause rapid bone loss and vertebral fracture risk.

Factor	EVENITY	Prolia
Active ingredient	Romosozumab-aqqg	Denosumab
Mechanism	Sclerostin inhibition	RANKL inhibition
Treatment schedule	Monthly for 12 months	Every six months
Main effect	Increases bone formation and reduces resorption	Reduces bone resorption
Typical role	Initial therapy for very high fracture risk	Long-term antiresorptive therapy
Key safety limitation	Cardiovascular boxed warning	Hypocalcemia, infections, osteonecrosis of jaw, atypical femoral fracture
Follow-on therapy	Required after 12 doses if treatment continues	Required when discontinuing to reduce rebound bone loss
Commercial relationship	Can initiate a patient	Can retain the patient after EVENITY

This sequencing gives Amgen a commercial advantage that standalone anabolic competitors do not have. It also means EVENITY sales should be evaluated alongside the durability of Prolia revenue rather than as an isolated product.

What are the financial results and revenue trajectory for EVENITY?

Amgen’s reported EVENITY sales have grown rapidly from a small launch base.

Year	Approximate global sales	Trajectory
2021	$0.5 billion range	Early international expansion
2022	$0.75 billion range	Strong uptake in the United States and Europe
2023	About $1.0 billion	Billion-dollar franchise scale
2024	Continued growth reported by Amgen	Expansion tempered by access and treatment duration

Amgen’s annual reports identify higher unit demand, broader geographic availability, and increased use in patients at high fracture risk as principal drivers of growth. UCB also recognizes revenue from its commercial collaboration with Amgen, especially in territories where UCB participates in commercialization. [1, 3]

The product’s revenue ceiling is shaped by treatment duration. A patient generally receives only 12 months of EVENITY, unlike a chronic antiresorptive used for several years. Growth therefore requires a continuing flow of new patients, increased penetration among high-risk patients, and expansion in countries where diagnosis and treatment rates remain low.

Key revenue drivers

The main factors supporting EVENITY revenue are:

Greater recognition of very high fracture risk.
Guideline support for anabolic or bone-forming therapy before antiresorptive treatment in selected patients.
Improved diagnosis after osteoporotic fractures.
Growth in specialty and endocrinology prescribing.
Use as part of an Amgen-controlled EVENITY-to-Prolia treatment sequence.
Expansion in Japan, Europe, and other markets.

Principal revenue risks

The main risks are:

Cardiovascular restrictions that exclude or deter some patients.
High treatment cost compared with oral bisphosphonates.
Prior authorization and step-therapy requirements.
The 12-dose lifetime treatment limitation in the U.S. label.
Competition from Tymlos and Forteo in the bone-building segment.
Limited willingness to use injectable treatment in moderate-risk patients.
Potential follow-on competition after biologic exclusivity and relevant patents expire.

When does EVENITY lose exclusivity?

U.S. regulatory exclusivity for EVENITY is expected to run for 12 years from the April 2019 approval of romosozumab-aqqg, subject to any applicable pediatric extension or other statutory adjustment. The reference-product exclusivity period therefore points to April 2031 as the principal U.S. biosimilar entry milestone. [2, 4]

Biologic exclusivity does not eliminate patent risk before 2031. A biosimilar applicant may seek approval before the end of regulatory exclusivity and may challenge patents through the Biologics Price Competition and Innovation Act process. Commercial launch would still depend on patent resolution, settlement, licensing, or expiration.

The relevant protection is likely to include several layers:

Protection category	Commercial relevance
Antibody composition patents	Protect the anti-sclerostin antibody or defined antibody sequences
Binding and functional claims	Cover interaction with sclerostin and biological activity
Formulation patents	May protect concentration, buffers, stabilizers, or injectable presentation
Manufacturing patents	May cover cell culture, purification, or product-quality processes
Method-of-use patents	May cover osteoporosis treatment, fracture reduction, or sequencing
Regulatory exclusivity	Blocks approval of a biosimilar for the statutory period

The strongest practical barrier is the combination of biologic manufacturing complexity, reference-product exclusivity, patent families, and clinical requirements for biosimilar development. Formulation and manufacturing patents may delay entry even if broad composition claims are vulnerable.

What is the Orange Book and Purple Book status of EVENITY?

EVENITY is a biologic, so its principal U.S. listing is in the FDA’s Purple Book rather than the Orange Book. The Orange Book is used primarily for approved small-molecule drugs and their listed patents. [4, 5]

The Purple Book identifies the reference product and biosimilar-related information. A future biosimilar applicant would use the BPCIA patent-exchange process rather than an ANDA Paragraph IV filing.

Are there Paragraph IV challenges to EVENITY?

A conventional Paragraph IV ANDA challenge is not the expected pathway for EVENITY because romosozumab is regulated as a biologic. The relevant challenge would be a biosimilar application under the BPCIA, accompanied by the statutory patent information exchange and potential district-court litigation.

Through publicly available FDA and company materials reviewed for this analysis, no approved U.S. biosimilar to romosozumab and no publicly reported U.S. biosimilar launch challenge to EVENITY had emerged. The absence of a current challenge does not remove future entry risk as the 2031 regulatory-exclusivity date approaches.

How strong is the EVENITY patent estate?

EVENITY has a comparatively strong commercial protection profile through the end of the 2020s because it combines biologic exclusivity with patent protection and manufacturing complexity. Its estate is stronger than a single composition patent but less durable than a product with a broad, long-lived small-molecule patent portfolio extending deep into the 2030s.

Composition and antibody protection

The core scientific protection relates to antibodies that bind sclerostin and inhibit its activity. These claims may be drafted around antibody sequences, binding epitopes, functional activity, or combinations of structural and functional limitations.

The value of these patents depends on claim breadth. A biosimilar with a highly similar antibody may face infringement risk under sequence, epitope, or functional claims. A narrow claim covering a particular sequence or formulation provides less leverage if a competitor can design around it.

Formulation and device protection

Commercial protection may also include the injectable formulation and presentation. These patents can cover:

Antibody concentration.
Buffer and stabilizer systems.
Subcutaneous administration.
Prefilled syringes or injection components.
Storage and stability conditions.

Formulation claims are usually less decisive than composition claims but can increase the cost and complexity of a biosimilar launch.

Manufacturing and process barriers

Romosozumab is produced in mammalian cell culture and requires controlled purification, analytical characterization, and manufacturing comparability. A biosimilar sponsor must demonstrate a high degree of similarity in quality attributes, pharmacokinetics, immunogenicity, and clinical performance as required by the FDA pathway.

Manufacturing know-how is not a substitute for patent protection, but it can delay entry and increase development expense. This favors the incumbent, particularly where the commercial opportunity is limited by a 12-month treatment course.

What licensing deals control EVENITY commercialization?

EVENITY originated from research involving UCB and Amgen. The companies developed the product under a collaboration in which Amgen has major commercial responsibilities in the United States and other markets, while UCB retains commercial rights or participation in specified territories.

The collaboration is strategically important because it divides economics between the companies and gives Amgen access to a bone-building product that complements Prolia. UCB benefits from participation in a high-value osteoporosis franchise without bearing all global development and commercialization costs. Public filings from both companies describe collaboration revenue, milestone economics, and territory-specific rights. [1, 3]

What litigation and settlement risks affect EVENITY?

No major public U.S. patent litigation involving a commercial romosozumab biosimilar was identified through the reviewed public records. The more significant litigation risk is prospective.

A future biosimilar dispute could involve:

Patent-listing and disclosure disputes under the BPCIA.
Antibody sequence or epitope claims.
Formulation and injection-device claims.
Manufacturing-process patents.
Injunction requests before commercial launch.
Settlement agreements setting a launch date before patent expiration.
Royalty-bearing licenses or territorial launch arrangements.

A settlement could permit an earlier biosimilar launch than the full patent term while preserving some protection for Amgen and UCB. For biologics, negotiated entry dates are common strategic outcomes because litigation costs are high and the parties can trade launch timing against royalties or other commercial terms.

What generic or biosimilar entry scenarios exist for EVENITY?

Scenario 1: Entry near 2031

This is the clearest base-case pathway if regulatory exclusivity remains the principal barrier and no earlier settlement is reached. A biosimilar sponsor could launch after the 12-year reference-product exclusivity period, subject to patent resolution.

Scenario 2: Earlier licensed entry

Amgen or UCB could license a biosimilar sponsor to enter before the end of all patent terms. The agreement could include royalties, a delayed launch date, or geographic limitations.

Scenario 3: Patent litigation delays entry

A biosimilar applicant could obtain FDA approval but delay commercial launch while litigating patents or negotiating a settlement. This would extend practical exclusivity beyond the regulatory date.

Scenario 4: Limited initial competition

Because EVENITY is administered for only 12 months and targets a high-risk population, the first biosimilar may face a smaller market than biosimilars to chronic biologics. Price discounts could be meaningful, but prescribers and payers may prioritize clinical sequencing and cardiovascular risk over price alone.

How does EVENITY compare with other anabolic osteoporosis drugs?

Product	Company	Mechanism	Duration or use profile	Main commercial issue
EVENITY	Amgen/UCB	Sclerostin inhibition	Monthly for 12 months	Cardiovascular boxed warning
Tymlos	Radius Health	PTHrP receptor agonist	Limited anabolic course	Smaller commercial scale and injection burden
Forteo	Eli Lilly and generic manufacturers	Teriparatide, PTH analog	Limited anabolic course	Generic and follow-on competition
Prolia	Amgen	RANKL inhibition	Long-term six-month dosing	Discontinuation rebound risk
Bisphosphonates	Multiple companies	Bone resorption inhibition	Long-term or intermittent	Low-cost generic competition

EVENITY has an efficacy and convenience advantage over daily anabolic injections, but Prolia has a simpler long-term maintenance position. Tymlos and Forteo compete for the same high-risk treatment population but have different safety, administration, and reimbursement profiles.

What is the FDA regulatory status of EVENITY?

EVENITY is FDA-approved for postmenopausal women with osteoporosis at high risk for fracture. Its U.S. approval is subject to:

A 12-month treatment limit.
A boxed warning for myocardial infarction, stroke, and cardiovascular death.
A recommendation to avoid initiation after a recent myocardial infarction or stroke.
Follow-on antiresorptive treatment for patients requiring ongoing therapy.

The regulatory profile supports use in carefully selected high-risk patients rather than broad first-line treatment. European and other national labels may differ in wording, reimbursement, and cardiovascular restrictions, affecting geographic sales mix.

Key Takeaways

EVENITY is a major osteoporosis biologic with global sales around or above $1 billion annually.
Its commercial model depends on new patient starts because treatment is limited to 12 monthly doses.
The product benefits from Amgen’s ability to transition patients to Prolia after the EVENITY course.
U.S. biologic exclusivity points to April 2031 as the principal biosimilar approval milestone.
The FDA Purple Book, not the Orange Book, is the relevant U.S. biologic reference-product framework.
No approved U.S. romosozumab biosimilar or major public biosimilar litigation was identified in the reviewed records.
Cardiovascular labeling is the main clinical and commercial limitation.
Formulation, manufacturing, antibody, and method-of-use patents may extend practical protection beyond core regulatory exclusivity.
Generic oral bisphosphonates limit expansion into lower-risk patients.
The likely first-entry pathway is a biosimilar launch near or after 2031, unless litigation or licensing produces an earlier negotiated entry.

FAQs About EVENITY Market and Patent Risk

Is EVENITY a biologic or a small-molecule drug?

EVENITY is a biologic monoclonal antibody. Its active ingredient is romosozumab-aqqg, an antibody that inhibits sclerostin.

Can patients take EVENITY for more than one year?

The U.S. label limits treatment to 12 monthly doses. Patients who need additional therapy should generally transition to an antiresorptive osteoporosis treatment.

Will an EVENITY biosimilar automatically substitute at the pharmacy?

No. Biosimilar approval and interchangeability are separate regulatory concepts. Pharmacy substitution depends on FDA interchangeability status and state law.

Does Amgen own all EVENITY rights worldwide?

No. EVENITY was developed through an Amgen-UCB collaboration. Commercial rights and economics vary by territory under the companies’ agreements.

What is the largest commercial threat to EVENITY before biosimilar entry?

The largest near-term threats are cardiovascular risk restrictions, payer step therapy, low-cost bisphosphonates, and competing anabolic therapies. Patent expiry is a later-stage risk than market access and treatment sequencing.

References

Amgen Inc. (2024). 2023 annual report. https://www.amgen.com
U.S. Food and Drug Administration. (2019). EVENITY (romosozumab-aqqg) prescribing information. https://www.accessdata.fda.gov
UCB. (2024). Annual report 2023. https://www.ucb.com
U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugsatfda

High Confidence Patents:	0
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for EVENITY

EVENITY Drug Profile

Summary for Tradename: EVENITY

Recent Clinical Trials for EVENITY

Note on Biologic Patents

1) High Certainty: US Patents for EVENITY Derived from Brand-Side Litigation

2) High Certainty: US Patents for EVENITY Derived from DrugPatentWatch Analysis and Company Disclosures

3) Low Certainty: US Patents for EVENITY Derived from Patent Text Search

EVENITY Market Dynamics, Financial Trajectory, Patent Protection, and Competitive Outlook